Plain-English translation of NCT06029270 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding (a newer immunotherapy drug) to (a standard immunotherapy) helps people with advanced nasopharyngeal cancer that has come back or spread. You would first receive six cycles of combination chemotherapy and together, and then continue on maintenance treatment for up to two years. Half of participants will continue alone, and half will receive plus together.
Nasopharyngeal cancer associated with Epstein-Barr virus can be difficult to treat, especially when it returns or spreads to other parts of the body. Researchers believe that combining two different immunotherapy drugs might work better than one drug alone to keep cancer from growing or coming back.
You likely qualify if…
You likely don't qualify if…
You would start by receiving six cycles of combination treatment (chemotherapy plus infusions), given every three weeks at a clinic. After that, you would be randomly assigned to receive either alone or plus as maintenance therapy, continuing every four weeks for up to two years. Throughout the trial, you would have regular scans (CT or MRI) and blood tests to monitor how well the treatment is working and to check for side effects.
AI-generated summary from trial data · Aug 13, 2026 · Not medical advice
United States